EBS Emergent BioSolutions Inc.

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world​, today announced that Joe C. Papa, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 PM PST.

The audio link for Emergent's session may be accessed  and will be live for up to 30 days.

The company’s slides will be made available at the time of the presentation on the of the Emergent website.

About Emergent BioSolutions

At Emergent, our mission is to protect and enhance life. For over 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we help protect public health, visit our  and follow us on , , ,  and . 

Investor Contact:

Richard S. Lindahl

Executive Vice President, CFO

Media Contact:

Assal Hellmer

Vice President, Communications



EN
08/01/2025

Underlying

EBSEmergent BioSolutions Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Emergent BioSolutions Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 48.51
DB1 Deutsche Boerse...
HSBA HSBC Holdings P... ... (+11)

Vermilion Int'l Compass: Global Equity Strategy

Opportunity Within Europe and Japan Our bullish outlook on global equities (MSCI ACWI) remains intact. We view this pullback as a buying opportunity and we are watching for $116-$117 support to hold on ACWI-US; this is an important resistance-turned-support level dating back to July 2024. Europe and Japan are on the cusp of major breakouts above critical resistance levels of 5000-5120 on the EURO STOXX 50 and 2740-2820 on the TOPIX. Europe has been consolidating for nine months, while Japan has...

DB1 DEUTSCHE BOERSE AG
HSBA HSBC HOLDINGS PLC
RY. ROYAL BANK OF CANADA
EBS EMERGENT BIOSOLUTIONS INC.
NB2 NORTHERN DATA AG
8306 MITSUBISHI UFJ FINANCIAL GROUP INC.
8316 SUMITOMO MITSUI FINANCIAL GROUP INC.
600919 BANK OF JIANGSU CO. LTD. CLASS A
CBA CEIBA INVESTMENTS
TPEIR PIRAEUS FINANCIAL HLDGS SA
WISE THEMES GENERATIVE ARTIFICIAL INTELLIGENCE ETF
6h / 35m 6h / 35m 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Health...

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world​, today announced that Joe C. Papa, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 PM PST. The audio link for Emergent's session may be accessed  and will be live for up...

January 8, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Announces Exercise of $20 Million Option to Supp...

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed) GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (DoD). The first delivery, which was valued at approximately $7 million began in December 2024, and remaining deliveries are expected in 2025. “We’re pleased to continue our work...

January 8, 2025 1 EN
 PRESS RELEASE
Free
EBS Emergent BioSol...

Emergent BioSolutions Receives $50 Million Contract Option from BARDA ...

Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) GAITHERSBURG, Md., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services has awarded a $50 million option to Emergent’s existing contract (HHSO100201600030C) for the acquisition of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuva...

December 16, 2024 1 EN
Free Trial
EBS Emergent BioSol...

Emergent Biosolutions Inc: 1 director

A director at Emergent Biosolutions Inc sold 25,000 shares at 10.910USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

EBS EMERGENT BIOSOLUTIONS INC.
11/15/24 November 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch